ÂÜÀòÂÒÂ×

Dr. Dennstedt earned his medical degree and his Master of Science in molecular genetics at the University of Vienna, Austria. He founded VBC-GENOMICS Bioscience Research GmbH (LLC), with two life science professors in 1999. A spin-off from the University of Vienna, VBC-Genomics rapidly gained a strong position within the Austrian biotech scene, based on its success as a service provider in oligonucleotide synthesis and custom sequencing. In research, the company focused on the development of diagnostic assays based on microarrays. The acquisition of VBC-Genomics by an international company ten years later, enabled Dr. Dennstedt to make a series of additional investments in and contributions to the life science space.

As CEO of the sequencing and oligonucleotide service provider, VBC-Biotech, located at the Vienna Biotech Campus, he structured the acquisition of VBC-Biotech by Eurofins in 2011. He was also an investor in and advisor to Genosense Diagnostics, a pioneer of preventive genetic diagnostics that allows physicians and patients to use genetic information for disease prevention.

In 2009, Dr. Martin Huber and Dr. Dennstedt founded Quantapore Inc. with the ambition of commercializing a single molecule, nanopore sequencing platform and revolutionizing the field of DNA sequencing.

In 2016, Dr. Dennstedt and Dr. Christian Harwanegg, with whom Dr. Dennstedt was a peer during the early days of VBC-Genomics, founded Macroarray Diagnostics (MADx), a multiplex allergy testing platform.

Dr. Dennstedt continues to broaden his knowledge base. He is currently earning his Master of Science in digital currencies, at the University of Nicosia, Cyprus. By developing complementary skills in blockchain technology and life sciences, he is poised to continue to be an industry thought leader as AI, blockchain technology, and big data play larger and larger roles in our futures.